Last reviewed · How we verify
123I-meta-iodobenzylguanidine
123I-meta-iodobenzylguanidine is a radiolabeled imaging agent that accumulates in neuroendocrine tumors and the sympathetic nervous system, allowing visualization via nuclear scintigraphy.
123I-meta-iodobenzylguanidine is a radiolabeled imaging agent that accumulates in neuroendocrine tumors and the sympathetic nervous system, allowing visualization via nuclear scintigraphy. Used for Imaging of neuroendocrine tumors including pheochromocytoma and paraganglioma, Imaging of carcinoid tumors, Assessment of sympathetic nervous system function.
At a glance
| Generic name | 123I-meta-iodobenzylguanidine |
|---|---|
| Sponsor | Vancouver Coastal Health |
| Drug class | Radiopharmaceutical; diagnostic imaging agent |
| Target | Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Nuclear Medicine; Endocrinology |
| Phase | Phase 3 |
Mechanism of action
This radiopharmaceutical is an iodine-123 labeled analog of guanethidine that mimics norepinephrine and is taken up by the norepinephrine transporter (NET) in neuroendocrine cells and sympathetic nerve terminals. Once accumulated in target tissues, the radioactive iodine-123 emits gamma radiation that can be detected by gamma cameras to create diagnostic images. It is used primarily for imaging neuroendocrine tumors such as pheochromocytoma, paraganglioma, and carcinoid tumors.
Approved indications
- Imaging of neuroendocrine tumors including pheochromocytoma and paraganglioma
- Imaging of carcinoid tumors
- Assessment of sympathetic nervous system function
Common side effects
- Radiation exposure
- Allergic reaction to iodine
- Thyroid uptake of free iodide
Key clinical trials
- Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma (PHASE2)
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
- Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) (PHASE2)
- Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma
- MIBG in Aging and Neurologic Disorders (PHASE4)
- Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors (EARLY_PHASE1)
- Evaluating Myocardial Ischemia in Chest Pain Using Exercise CMR
- Study Of the Safety of Locally Manufactured 123I-metaiodobenzylguanidine(MIBG) in Routine Clinical Use
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 123I-meta-iodobenzylguanidine CI brief — competitive landscape report
- 123I-meta-iodobenzylguanidine updates RSS · CI watch RSS
- Vancouver Coastal Health portfolio CI